Eplivanserin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Eplivanserin
Accession Number
DB12177  (DB06392)
Type
Small Molecule
Groups
Investigational
Description

Eplivanserin has been used in trials studying the treatment of Sleep, Insomnia, Chronic Pain, Fibromyalgia, and Primary Insomnia, among others.

Structure
Thumb
Synonyms
  • Eplivanserine
External IDs
SR 46349 / SR-46349 / SR46349
Categories
UNII
3CO94WO6DJ
CAS number
130579-75-8
Weight
Average: 328.387
Monoisotopic: 328.158706087
Chemical Formula
C19H21FN2O2
InChI Key
VAIOZOCLKVMIMN-PRJWTAEASA-N
InChI
InChI=1S/C19H21FN2O2/c1-22(2)13-14-24-21-19(17-5-3-4-6-18(17)20)12-9-15-7-10-16(23)11-8-15/h3-12,23H,13-14H2,1-2H3/b12-9+,21-19-
IUPAC Name
4-[(1E,3Z)-3-{[2-(dimethylamino)ethoxy]imino}-3-(2-fluorophenyl)prop-1-en-1-yl]phenol
SMILES
CN(C)CCO\N=C(\C=C\C1=CC=C(O)C=C1)/C1=CC=CC=C1F

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
U5-hydroxytryptamine receptor 2ANot AvailableHuman
U5-hydroxytryptamine receptor 2CNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabEplivanserin may increase the anticoagulant activities of Abciximab.Approved
AcenocoumarolEplivanserin may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Acetylsalicylic acid.Approved, Vet Approved
AloxiprinThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Aloxiprin.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Eplivanserin.Approved, Investigational
AlteplaseEplivanserin may increase the anticoagulant activities of Alteplase.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Aminosalicylic Acid.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Eplivanserin.Approved
AncrodEplivanserin may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Eplivanserin.Investigational
AnistreplaseEplivanserin may increase the anticoagulant activities of Anistreplase.Approved
Antithrombin III humanEplivanserin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Apixaban.Approved
AprotininThe therapeutic efficacy of Eplivanserin can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArdeparinEplivanserin may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanEplivanserin may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinEplivanserin may increase the anticoagulant activities of Astaxanthin.Investigational
AzelastineAzelastine may increase the anticoagulant activities of Eplivanserin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Balsalazide.Approved, Investigational
BatroxobinEplivanserin may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminEplivanserin may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinEplivanserin may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BeraprostBeraprost may increase the anticoagulant activities of Eplivanserin.Investigational
BivalirudinEplivanserin may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BrinaseEplivanserin may increase the anticoagulant activities of Brinase.Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Eplivanserin.Experimental
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Eplivanserin.Approved
ButylphthalideButylphthalide may increase the anticoagulant activities of Eplivanserin.Investigational
CangrelorCangrelor may increase the anticoagulant activities of Eplivanserin.Approved
CaplacizumabEplivanserin may increase the anticoagulant activities of Caplacizumab.Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Carbaspirin calcium.Experimental, Investigational
CertoparinEplivanserin may increase the anticoagulant activities of Certoparin.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Eplivanserin.Approved
CilostazolCilostazol may increase the anticoagulant activities of Eplivanserin.Approved, Investigational
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Eplivanserin.Approved, Investigational
ClindamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Eplivanserin.Approved, Vet Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Eplivanserin.Approved
CloricromenEplivanserin may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneEplivanserin may increase the anticoagulant activities of Clorindione.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Eplivanserin.Approved, Illicit
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Collagenase clostridium histolyticum.Approved, Investigational
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Eplivanserin.Approved
Dabigatran etexilateEplivanserin may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinEplivanserin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidEplivanserin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanEplivanserin may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Eplivanserin.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Eplivanserin.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Dersalazine.Investigational
DesirudinEplivanserin may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseEplivanserin may increase the anticoagulant activities of Desmoteplase.Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Eplivanserin.Approved
DextranEplivanserin may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DicoumarolEplivanserin may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Diflunisal.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Eplivanserin.Approved
DiphenadioneEplivanserin may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Eplivanserin.Approved
DitazoleEplivanserin may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Eplivanserin.Approved, Vet Approved
Drotrecogin alfaEplivanserin may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
Edetic AcidEplivanserin may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEplivanserin may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinEplivanserin may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the anticoagulant activities of Eplivanserin.Approved, Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Eplivanserin.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Eplivanserin.Approved, Investigational
EthanolEplivanserin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
Ethyl biscoumacetateEplivanserin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ferulic acidEplivanserin may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinEplivanserin may increase the anticoagulant activities of Fibrinolysin.Investigational
FluindioneEplivanserin may increase the anticoagulant activities of Fluindione.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Eplivanserin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Fluvoxamine.Approved, Investigational
FondaparinuxEplivanserin may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexateEplivanserin may increase the anticoagulant activities of Gabexate.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Eplivanserin.Approved, Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Guacetisal.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Eplivanserin.Approved, Investigational
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Hemoglobin crosfumaril.Experimental
HeparinEplivanserin may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineEplivanserin may increase the anticoagulant activities of Higenamine.Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Eplivanserin.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Eplivanserin.Approved
IbudilastIbudilast may increase the anticoagulant activities of Eplivanserin.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Eplivanserin.Approved, Investigational, Nutraceutical
IdraparinuxEplivanserin may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Eplivanserin.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Eplivanserin.Investigational
IloprostIloprost may increase the anticoagulant activities of Eplivanserin.Approved, Investigational
IndobufenEplivanserin may increase the anticoagulant activities of Indobufen.Investigational
KetanserinKetanserin may increase the anticoagulant activities of Eplivanserin.Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Eplivanserin.Approved, Investigational
LepirudinEplivanserin may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanEplivanserin may increase the anticoagulant activities of Letaxaban.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Eplivanserin.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Eplivanserin.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Eplivanserin.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Eplivanserin.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Eplivanserin.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Magnesium citrate is combined with Eplivanserin.Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Eplivanserin.Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Eplivanserin.Approved
MelagatranEplivanserin may increase the anticoagulant activities of Melagatran.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Mesalazine.Approved
MilrinoneMilrinone may increase the anticoagulant activities of Eplivanserin.Approved
NadroparinEplivanserin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatEplivanserin may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilNaftopidil may increase the anticoagulant activities of Eplivanserin.Investigational
NimesulideNimesulide may increase the anticoagulant activities of Eplivanserin.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Nitroaspirin.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Obinutuzumab.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Olsalazine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Eplivanserin.Approved, Nutraceutical
OtamixabanEplivanserin may increase the anticoagulant activities of Otamixaban.Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Eplivanserin.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Eplivanserin.Approved, Investigational, Vet Approved
OzagrelEplivanserin may increase the anticoagulant activities of Ozagrel.Investigational
ParnaparinEplivanserin may increase the anticoagulant activities of Parnaparin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Paroxetine.Approved, Investigational
Pentaerythritol TetranitrateEplivanserin may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Eplivanserin.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Eplivanserin.Approved, Investigational
PhenindioneEplivanserin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Eplivanserin.Approved, Investigational
PhenprocoumonEplivanserin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Phenyl aminosalicylate.Approved
PicotamideEplivanserin may increase the anticoagulant activities of Picotamide.Experimental
Potassium CitrateEplivanserin may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PramipexoleEplivanserin may increase the sedative activities of Pramipexole.Approved, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Eplivanserin.Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Eplivanserin.Approved, Investigational
Protein CEplivanserin may increase the anticoagulant activities of Protein C.Approved
Protein S humanEplivanserin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEplivanserin may increase the anticoagulant activities of Protocatechualdehyde.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Pseudoephedrine.Approved
PyrantelThe risk or severity of adverse effects can be increased when Pyrantel is combined with Eplivanserin.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Eplivanserin.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Eplivanserin.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Eplivanserin.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Eplivanserin.Approved, Experimental, Investigational
ReteplaseEplivanserin may increase the anticoagulant activities of Reteplase.Approved, Investigational
ReviparinEplivanserin may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Eplivanserin.Approved
RivaroxabanEplivanserin may increase the anticoagulant activities of Rivaroxaban.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Eplivanserin.Approved
SarpogrelateSarpogrelate may increase the anticoagulant activities of Eplivanserin.Investigational
SaruplaseEplivanserin may increase the anticoagulant activities of Saruplase.Experimental
SelexipagEplivanserin may increase the anticoagulant activities of Selexipag.Approved
SevofluraneSevoflurane may increase the anticoagulant activities of Eplivanserin.Approved, Vet Approved
SRT501SRT501 may increase the anticoagulant activities of Eplivanserin.Investigational
StreptokinaseEplivanserin may increase the anticoagulant activities of Streptokinase.Approved, Investigational
SulodexideEplivanserin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Eplivanserin.Approved, Investigational
TenecteplaseEplivanserin may increase the anticoagulant activities of Tenecteplase.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Eplivanserin.Investigational
TicagrelorEplivanserin may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Eplivanserin.Approved
TinzaparinEplivanserin may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolEplivanserin may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Eplivanserin.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Eplivanserin.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Eplivanserin.Approved
TositumomabThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Tositumomab.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Eplivanserin.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Eplivanserin.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Eplivanserin.Approved
TreprostinilEplivanserin may increase the anticoagulant activities of Treprostinil.Approved, Investigational
TriflusalTriflusal may increase the anticoagulant activities of Eplivanserin.Approved, Investigational
TroxerutinEplivanserin may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseEplivanserin may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
Vitamin EVitamin E may increase the antiplatelet activities of Eplivanserin.Approved, Nutraceutical, Vet Approved
VorapaxarVorapaxar may increase the anticoagulant activities of Eplivanserin.Approved
WarfarinEplivanserin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranEplivanserin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Eplivanserin.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5486684
PubChem Substance
347828464
ChemSpider
13267837
ChEMBL
CHEMBL257704
Wikipedia
Eplivanserin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentSleep Initiation and Maintenance Disorders1
2CompletedTreatmentFibromyalgia / Pain, Chronic / Sleep1
3CompletedTreatmentPrimary Insomnia1
3CompletedTreatmentSleep Initiation and Maintenance Disorders1
3CompletedTreatmentSleep Initiation and Maintenance Disorders / Sleeplessness3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00672 mg/mLALOGPS
logP3.48ALOGPS
logP3.98ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)9.47ChemAxon
pKa (Strongest Basic)7.81ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area45.06 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity95.4 m3·mol-1ChemAxon
Polarizability36.1 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as cinnamylphenols. These are organic compounds containing the 1,3-diphenylpropene moiety with one benzene ring bearing one or more hydroxyl groups.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Linear 1,3-diarylpropanoids
Sub Class
Cinnamylphenols
Direct Parent
Cinnamylphenols
Alternative Parents
Styrenes / Fluorobenzenes / 1-hydroxy-2-unsubstituted benzenoids / Aryl fluorides / Trialkylamines / Organooxygen compounds / Organofluorides / Hydrocarbon derivatives
Substituents
Cinnamylphenol / Styrene / Fluorobenzene / Halobenzene / Phenol / 1-hydroxy-2-unsubstituted benzenoid / Aryl fluoride / Monocyclic benzene moiety / Aryl halide / Benzenoid
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da

Drug created on October 20, 2016 15:33 / Updated on August 11, 2018 17:00